Communiqués Pharma Mar, S.A.

Actions

PHM

ES0169501022

Marché Fermé - BME Autres places de cotation 17:35:13 28/06/2024			Après clotûre 21:05:52
31,82 ^EUR	-2,69%		31,76	-0,19%

04/06	Pharma Mar présente des résultats encourageants à l'ASCO pour le cancer du poumon à petites cellules	CI
23/04	Pharma Mar, S.A. présente ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers	30/01	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05/12	AQ
PharmaMar receives a payment of 10 million dollars from Janssen as a commercial milestone	07/11	AQ
PharmaMar presents new data on lurbinectedin for small cell lung cancer at ESMO 2023	19/10/23	AQ
PharmaMar increased investment in R&D in oncology by 23% in 2022	25/09/23	AQ
PharmaMar licenses lurbinectedin to Key Oncologics for marketing and distribution in Africa	13/09/23	AQ
PharmaMar will present new data on lurbinectedin at the IASLC 2023 World Lung Cancer Congress	11/09/23	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Oman	20/07/23	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan	12/07/23	AQ
PharmaMar and Luye Pharma announce the acceptance of the registration application for the approval of lurbinectedin in China	07/06/23	AQ
PharmaMar announces abstracts to be presented at ASCO 2023	29/05/23	AQ
European Commission grants orphan drug designation to PharmaMar's lurbinectedin for the treatment of soft tissue sarcoma	15/05/23	AQ
PharmaMar starts the Nereida clinical trial with plitidepsin for the treatment of immunosuppressed patients with COVID-19	21/04/23	AQ
PharmaMar announces the approval of Zepzelca for the treatment of metastatic small cell lung cancer in Switzerland	09/03/23	AQ
PharmaMar closes the recruitment of the phase III Neptuno study with plitidepsin for the treatment of COVID-19	17/02/23	AQ
PharmaMar maintains that there was a conflict of interest in the case of Aplidin	07/02/23	AQ
PharmaMar announces the approval of Zepzelca (lurbinectedin) for the treatment of metastatic small cell lung cancer in Israel	01/02/23	AQ
PharmaMar receives orphan drug designation for lurbinectedin from the Swiss Agency for Therapeutic Products for malignant mesothelioma	28/12/22	AQ
PharmaMar leads the ONCOLIBERYX consortium together with four research centers for the development of new strategies for the administration of oncological drugs of marine origin	05/12/22	AQ
PharmaMar - The PROFARMA program grants PharmaMar an 'Excellent' company rating	17/10/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Pharma Mar, S.A.

Actions

PHM

ES0169501022

Communiqués

Filtres